Literature DB >> 31948939

Towards Multidrug Adaptive Therapy.

Robert A Gatenby1, Joel S Brown1,2, Paul K Newton3, Alexander R A Anderson4, Jeffrey West4, Li You5, Jingsong Zhang6.   

Abstract

A new ecologically inspired paradigm in cancer treatment known as "adaptive therapy" capitalizes on competitive interactions between drug-sensitive and drug-resistant subclones. The goal of adaptive therapy is to maintain a controllable stable tumor burden by allowing a significant population of treatment-sensitive cells to survive. These, in turn, suppress proliferation of the less-fit resistant populations. However, there remain several open challenges in designing adaptive therapies, particularly in extending these therapeutic concepts to multiple treatments. We present a cancer treatment case study (metastatic castrate-resistant prostate cancer) as a point of departure to illustrate three novel concepts to aid the design of multidrug adaptive therapies. First, frequency-dependent "cycles" of tumor evolution can trap tumor evolution in a periodic, controllable loop. Second, the availability and selection of treatments may limit the evolutionary "absorbing region" reachable by the tumor. Third, the velocity of evolution significantly influences the optimal timing of drug sequences. These three conceptual advances provide a path forward for multidrug adaptive therapy. SIGNIFICANCE: Driving tumor evolution into periodic, repeatable treatment cycles provides a path forward for multidrug adaptive therapy. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 31948939     DOI: 10.1158/0008-5472.CAN-19-2669

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

Review 1.  Characterizing the ecological and evolutionary dynamics of cancer.

Authors:  Nastaran Zahir; Ruping Sun; Daniel Gallahan; Robert A Gatenby; Christina Curtis
Journal:  Nat Genet       Date:  2020-07-27       Impact factor: 38.330

2.  Is the Fixed Periodic Treatment Effective for the Tumor System without Complete Information?

Authors:  Jiali Wang; Yixuan Zhang; Xiaoquan Liu; Haochen Liu
Journal:  Cancer Manag Res       Date:  2021-11-30       Impact factor: 3.989

Review 3.  The theory of tumor ecosystem.

Authors:  Xueman Chen; Erwei Song
Journal:  Cancer Commun (Lond)       Date:  2022-06-01

4.  GLUT1 production in cancer cells: a tragedy of the commons.

Authors:  Anuraag Bukkuri; Robert A Gatenby; Joel S Brown
Journal:  NPJ Syst Biol Appl       Date:  2022-06-29

Review 5.  Resistance to second-generation androgen receptor antagonists in prostate cancer.

Authors:  Keith T Schmidt; Alwin D R Huitema; Cindy H Chau; William D Figg
Journal:  Nat Rev Urol       Date:  2021-03-19       Impact factor: 14.432

6.  IsoMaTrix: a framework to visualize the isoclines of matrix games and quantify uncertainty in structured populations.

Authors:  Jeffrey West; Yongqian Ma; Artem Kaznatcheev; Alexander R A Anderson
Journal:  Bioinformatics       Date:  2020-12-16       Impact factor: 6.937

Review 7.  Optimizing the future: how mathematical models inform treatment schedules for cancer.

Authors:  Deepti Mathur; Ethan Barnett; Howard I Scher; Joao B Xavier
Journal:  Trends Cancer       Date:  2022-03-09

Review 8.  Regulation of Tumor Invasion by the Physical Microenvironment: Lessons from Breast and Brain Cancer.

Authors:  Garrett F Beeghly; Kwasi Y Amofa; Claudia Fischbach; Sanjay Kumar
Journal:  Annu Rev Biomed Eng       Date:  2022-02-04       Impact factor: 11.324

9.  The somatic molecular evolution of cancer: Mutation, selection, and epistasis.

Authors:  Krishna Dasari; Jason A Somarelli; Sudhir Kumar; Jeffrey P Townsend
Journal:  Prog Biophys Mol Biol       Date:  2021-08-06       Impact factor: 4.799

10.  Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy.

Authors:  Philip K Maini; Alexander R A Anderson; Maximilian A R Strobl; Jeffrey West; Yannick Viossat; Mehdi Damaghi; Mark Robertson-Tessi; Joel S Brown; Robert A Gatenby
Journal:  Cancer Res       Date:  2020-11-10       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.